Andere Sprachen RenovoRx, Inc.

Aktien

A3CYE8

US75989R1077

RNXT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 10.05.2024			% 5 Tage	% 1. Jan.
1.45 ^USD	+7.81%		+18.85%	-36.68%

16.04.	RenovoRx hebt die jüngste Präsentation eines Abstracts zu klinischen Daten auf der wissenschaftlichen Jahrestagung 2024 der Society of Interventional Radiology hervor	CI
01.04.	RenovoRx, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024	02.05.
RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement	19.04.
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement	18.04.
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech	16.04.
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16.04.
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16.04.
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026	15.04.
RenovoRx, Inc. announced that it has received $11.136652 million in funding	15.04.
RenovoRx Announces $11.1 Million at Market Private Placement	08.04.
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	08.04.
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	05.04.
RenovoRx, Inc. announced that it expects to receive $11.136652 million in funding	04.04.
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024	12.03.
RenovoRx Highlights Key Leadership Promotions	11.03.
RenovoRx Highlights Key Leadership Promotions	08.03.
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	23.02.
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	09.02.
RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer	09.02.
RenovoRx CEO Issues Letter to Shareholders	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen RenovoRx, Inc.

Aktien

A3CYE8

US75989R1077

RNXT

Andere Sprachen

Filter